Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer.

Trial Profile

Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Exemestane (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms ELBA
  • Most Recent Events

    • 21 Nov 2009 Planned initiation date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 09 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top